Industry Briefs: Mar. 26, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Mar. 26, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Corcept Therapeutics has selected PharmaForm as its primary commercial manufacturer for its newly approved drug product, Korlym (mifepristone) for treating Cushing’s syndrome. Read More

Coronado Biosciences has signed a collaboration agreement with Dr. Falk Pharma and OvaMed for the development of trichuris suis ova for treating Crohn’s Disease. Read More

Elite Pharmaceuticals has signed an agreement with a private Hong Kong-based company to develop a branded prescription pharmaceutical product in the US. Read More

GE Healthcare has expanded its Shanghai Fast Trak training center to serve the growing biopharmaceutical industry in China.

Impax and Tolmar have multiproduct agreement for the development, supply, and distribution of alternative dosage-form products. Read More

Marken has completed all commissioning work for its new operational hub in Feltham, United Kingdom. Read More

People News

Adhesives Research appointed Steven Herbert to the position of manufacturing manager.

Albany Molecular Research has named Stephen Rossmeis senior manager to oversee the company's facilities at Burlington, Massachusetts aseptic-fill operations. Read More

Avrio Biopharmaceuticals has appointed William P. Botha as president. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here